EDGC Decides 83.33% Reverse Stock Split Under Rehabilitation Plan... Existing Shareholders Face Massive Dilution and Value Loss
Eone Diagnomics Genome Center (EDGC) decided an 83.33% capital reduction by merging 6 common shares into 1, following a court-approved rehabilitation plan. The new listing date was postponed by one day from June 1 to June 2, 2026.
In addition to the stock split, a third-party allotment for debt-to-equity conversion and a paid-in capital increase will be carried out sequentially, causing massive dilution risk for existing shareholders.
The fractional shares (17,291 shares) arising from the merger were canceled with court approval, but this has a negligible impact on overall shareholder value recovery.
[AI Comprehensive Analysis]This capital reduction is part of rehabilitation proceedings aimed at improving financial structure, but for existing shareholders, it is an extreme negative event resulting in over 83% reduction in equity value. Considering additional debt-to-equity conversion and capital increase, the actual ownership ratio and stock value of existing shareholders are expected to be significantly impaired.
KOSDAQ Filing Information
Filing: [Correction of Description] Report on Major Matters (Decision on Capital Reduction)
Company: Eone Diagnomics Genome Center (245620)
Submission: Eone Diagnomics Genome Center Co., Ltd.